NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis → Trump convicted... now what? (From Stansberry Research) (Ad) Free AKBA Stock Alerts $1.10 +0.04 (+3.77%) (As of 12:38 PM ET) Add Compare Share Share Today's Range$1.06▼$1.1250-Day Range$1.03▼$1.6352-Week Range$0.78▼$2.48Volume651,411 shsAverage Volume3.82 million shsMarket Capitalization$230.56 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Akebia Therapeutics alerts: Email Address Akebia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside354.5% Upside$5.00 Price TargetShort InterestHealthy5.58% of Shares Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.28) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.46 out of 5 starsMedical Sector244th out of 904 stocksPharmaceutical Preparations Industry111th out of 427 stocks 3.5 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.58% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 1.35%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 55.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.35. Previous Next 1.8 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.Search Interest20 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Akebia Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. But while the Left celebrates his conviction... and the Right rallies around him... the average American is not prepared for what happens next.Which is why it's so important to access this presentation while it's still available online. About Akebia Therapeutics Stock (NASDAQ:AKBA)Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AKBA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBA Stock News HeadlinesJune 3, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 23, 2024 | prnewswire.comAkebia Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 14, 2024 | prnewswire.comAkebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor ConferenceMay 11, 2024 | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)May 10, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comAkebia Therapeutics Reports Q1 2024 Financial Results: A Detailed OverviewMay 10, 2024 | finance.yahoo.comAkebia Therapeutics First Quarter 2024 Earnings: Misses ExpectationsMay 9, 2024 | seekingalpha.comAkebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comAKBA Stock Earnings: Akebia Therapeutics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | sfgate.comAkebia Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comAkebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 2, 2024 | finanznachrichten.deAkebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | prnewswire.comAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business HighlightsMay 1, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | stocknews.com4 Biotech Stocks to Watch Closely in MayApril 28, 2024 | finance.yahoo.comWhen Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?March 29, 2024 | msn.comBiggest stock movers today: AMC, PLTR, RH, and moreMarch 28, 2024 | finance.yahoo.comFDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated AnemiaMarch 28, 2024 | msn.comAkebia stock jumps as FDA clears renal anemia therapyMarch 28, 2024 | markets.businessinsider.comAkebia's Vafseo Tablets Approved By FDA For Anemia Treatment In Dialysis PatientsMarch 28, 2024 | bizjournals.comTwo years after initial rejection, Akebia’s anemia drug finally gets FDA approvalMarch 27, 2024 | reuters.comU.S. FDA approves Akebia's anemia drugMarch 27, 2024 | prnewswire.comAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisMarch 27, 2024 | finance.yahoo.comAkebia Awaits FDA Word On Second Crack At VadadustatMarch 17, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33See More Headlines Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/10/2024Next Earnings (Estimated)8/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees167Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+371.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,920,000.00 Net Margins-22.99% Pretax Margin-22.99% Return on EquityN/A Return on Assets-18.01% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.31 Sales & Book Value Annual Sales$194.62 million Price / Sales1.14 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-6.63Miscellaneous Outstanding Shares209,600,000Free Float201,003,000Market Cap$222.18 million OptionableOptionable Beta0.80 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. John P. Butler MBA (Age 60)CEO, President, Interim Principal Financial Officer & Director Comp: $1.81MMr. Michel Dahan (Age 45)Senior VP & COO Comp: $1.02MMs. Nicole R. Hadas J.D. (Age 51)Senior VP, Chief Legal Officer & Secretary Comp: $933.3kDr. Steven Keith Burke M.D. (Age 63)Senior VP of Research & Development and Chief Medical Officer Comp: $937.39kMr. Richard C. Malabre (Age 63)Chief Accounting Officer Ms. Kimberly GarkoSenior VP & Chief Technical OfficerTracey VetterickVice President of Portfolio Strategy & Corporate AdministrationMercedes CarrascoSenior Director of Investor & Corporate CommunicationsMs. Meredith BowmanSenior VP & Chief People OfficerMs. Carolyn RucciSenior Vice President of Legal & General CounselMore ExecutivesKey CompetitorsPuma BiotechnologyNASDAQ:PBYIUroGen PharmaNASDAQ:URGNRAPT TherapeuticsNASDAQ:RAPTMarinus PharmaceuticalsNASDAQ:MRNSTyra BiosciencesNASDAQ:TYRAView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 219,347 shares on 5/16/2024Ownership: 0.781%Lazard Asset Management LLCBought 43,545 shares on 5/15/2024Ownership: 0.021%Torno Capital LLCBought 5,800 shares on 5/15/2024Ownership: 0.000%Vanguard Group Inc.Bought 618,500 shares on 5/10/2024Ownership: 3.929%Acadian Asset Management LLCSold 1,605,748 shares on 5/10/2024Ownership: 2.536%View All Insider TransactionsView All Institutional Transactions AKBA Stock Analysis - Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKBA shares. View AKBA analyst ratings or view top-rated stocks. What is Akebia Therapeutics' stock price target for 2024? 2 brokerages have issued 1 year target prices for Akebia Therapeutics' shares. Their AKBA share price targets range from $4.00 to $6.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts. How have AKBA shares performed in 2024? Akebia Therapeutics' stock was trading at $1.24 at the beginning of the year. Since then, AKBA shares have decreased by 11.3% and is now trading at $1.10. View the best growth stocks for 2024 here. When is Akebia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 23rd 2024. View our AKBA earnings forecast. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). The biopharmaceutical company earned $32.61 million during the quarter, compared to the consensus estimate of $41.13 million. During the same quarter in the prior year, the firm posted ($0.14) EPS. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.93%), Acadian Asset Management LLC (2.54%), Jacobs Levy Equity Management Inc. (0.78%), Assenagon Asset Management S.A. (0.38%), Lazard Asset Management LLC (0.02%) and Cannon Global Investment Management LLC (0.01%). Insiders that own company stock include David A Spellman, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven Keith Burke and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKBA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.